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Summary
 
Recently, we demonstrated that major histocompatibility complex class I–restricted cross-pres-
entation of exogenous self-antigens can induce peripheral T cell tolerance by deletion of au-
toreactive CD8
 
1
 
 T cells. In these studies, naive ovalbumin (OVA)-specific CD8
 
1
 
 T cells from
the transgenic line OT-I were injected into transgenic mice expressing membrane-bound
OVA (mOVA) under the control of the rat insulin promoter (RIP) in pancreatic islets, kidney
proximal tubules, and the thymus. Cross-presentation of tissue-derived OVA in the renal and
pancreatic lymph nodes resulted in activation, proliferation, and then the deletion of OT-I
cells. In this report, we investigated the molecular mechanisms underlying this form of T cell
deletion. OT-I mice were crossed to tumor necrosis factor receptor 2 (TNFR2) knockout
mice and to CD95 (Fas, Apo-1) deficient mutant 
 
lpr
 
 mice. Wild-type and TNFR2-deficient
OT-I cells were activated and then deleted when transferred into RIP-mOVA mice, whereas
CD95-deficient OT-I cells were not susceptible to deletion by cross-presentation. Further-
more, cross-presentation led to upregulation of the CD95 molecule on the surface of wild-type
OT-I cells in vivo, consistent with the idea that this is linked to rendering autoreactive T cells
susceptible to CD95-mediated signaling. This study represents the first evidence that CD95 is
involved in the deletion of autoreactive CD8
 
1
 
 T cells in the whole animal.
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E
 
xogenous antigens derived from nonlymphoid tissues
can be presented by professional APCs to naive CD8
 
1
 
T cells by a mechanism termed cross-presentation. This
may be important for the induction of immunity to patho-
gens that avoid professional APCs (1, 2). Using transgenic
mice expressing membrane-bound OVA (mOVA) under
the control of the rat insulin promoter (RIP), we have
demonstrated that self-antigens can also gain access to the
cross-presentation pathway and activate autoreactive CD8
 
1
 
T cells in vivo (3). When transgenic OVA-specific CD8
 
1
 
 T
cells were injected into RIP-mOVA mice, which expressed
OVA in pancreatic islets, kidney proximal tubules, and the
thymus, they were activated in the renal and pancreatic
LNs. This form of activation initially led to proliferation
and then to the deletion of transgenic OVA-specific class
I–restricted CD8
 
1
 
 T (OT-I) cells (4). Thus, cross-presenta-
tion can induce peripheral tolerance by deleting autoreac-
tive CD8
 
1
 
 T cells. The molecular mechanisms underlying
this deletion have not been addressed in previous studies.
Programmed death of activated T cells can result either
passively from lack of survival factors such as IL-2 (death-
by-neglect) or actively by activation-induced cell death
(AICD), which is mediated by molecules of the TNFR su-
perfamily (5–7). CD95 (Fas, Apo-1), a member of this fam-
ily, is upregulated on the surface of T cells upon antigen-
induced activation, and induces apoptosis of activated T
cells when ligated in vitro (8–12). A mutation of the CD95
gene causes the 
 
lpr
 
 (lymphoproliferation) mutation in mice
characterized by lymphadenopathy and accumulation of
nonfunctional CD4
 
2
 
CD8
 
2
 
B220
 
1
 
TCR
 
1
 
 cells, and by au-
toimmune diseases such as immune-complex nephritis (13).
A similar pathology is seen in 
 
gld
 
 (generalized lymphopro-
liferative disease) mice, which carry a point mutation in the
CD95 ligand gene rendering this protein functionless (14).
Mutations in the human CD95 gene lead to a related clini-
cal picture, referred to as autoimmune lymphoproliferative
syndrome (15–17). Since thymic-negative selection does
not require functional CD95 (6, 18), these symptoms are
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thought to be caused by defects in the peripheral deletion
of activated T cells (7). Whereas in vitro studies have shown
a critical role of CD95 in the deletion of mature CD4
 
1
 
 T
cells, TNFR2 was suggested to mediate CD95-independent
deletion of CD8
 
1
 
 T cells (19). In vivo studies using TCR
transgenic mice have confirmed the key role of CD95 in
AICD of CD4
 
1
 
 T cells (6, 18, 20, 21). The roles of CD95
and TNFR2 in the peripheral deletion of CD8
 
1
 
 T cells have
not been extensively investigated, but there is evidence that
CD95 does not participate in peripheral deletion associated
with virus infection (22, 23). In this study, we investigated
the role of CD95 and TNFR2 in the deletion of CD8
 
1
 
 T
cells induced by cross-presentation of self-antigens.
 
Materials and Methods
 
Mice.
 
All mice were bred and maintained at the Walter and
Eliza Hall Institute for Medical Research. OT-I and RIP-mOVA
transgenic mice have been described previously (3). TNFR2-defi-
cient mice on a C57BL/6 (B6) background (24) and B6.
 
lpr
 
 mice
(The Jackson Laboratory, Bar Harbor, ME) were crossed to OT-I
mice. TNFR2 gene disruption and the presence of the 
 
lpr
 
 muta-
tion were confirmed by PCR.
 
Adoptive Transfer and FACS
 
Ò
 
 Analysis.
 
Preparation and adop-
tive transfer of OT-I cells, 5,6-carboxy-succinimidyl-fluorescein-
ester (CFSE)-labeling, and analysis on a FACScan
 
Ò
 
 (Becton
Dickinson, Mountain View, CA) were carried out as previously
described (4). In adoptive transfer experiments, OT-I cells were
identified in recipient mice by staining with FITC-conjugated
anti-V
 
a
 
2 (B20.1), PE-conjugated CD8 (Caltag Labs., So. San
Francisco, CA), and anti-V
 
b
 
5
 
1 
 
biotin-conjugated (MR9-40) re-
vealed with Streptavidin-Tricolor (Caltag Labs.). An average of
1.4% of CD8
 
1
 
 cells were V
 
a
 
2
 
1
 
V
 
b
 
5
 
1
 
 in uninjected mice. The
total number of OT-I cells was derived using the formula: (%
V
 
a
 
2
 
1
 
V
 
b
 
5
 
1
 
 cells in the CD8
 
1
 
 
 
cells 
 
2
 
1.4%) 
 
3 
 
(% CD8
 
1
 
 T cells
in live cells) 
 
3 
 
(number of live cells) as previously described (4).
Anti-V
 
a
 
2 TCR (B20.1) and anti-V
 
b
 
5.1/2 TCR mAbs were
prepared from hybridoma supernatants and conjugated to biotin
or to FITC using standard protocols. Dead cells were excluded by
propidium iodide. Biotinylated anti-CD95 (Jo2) was from
PharMingen (San Diego, CA).
 
Bone Marrow Chimeras.
 
RIP-mOVA mice expressing the MHC
class I molecule H-2K
 
b
 
 on bone marrow–derived cells, and H-2K
 
bm1
 
on non–bone marrow–derived tissue cells (B6
 
®
 
RIP-mOVA
mice.bm1) were generated by injecting 1–4 
 
3 
 
10
 
6
 
 fetal liver cells
from B6 embryos at days 14–16 after gestation into 900 cGy irra-
diated RIP-mOVA mice backcrossed to the bm1 haplotype. The
next day, radioresistant T cells were depleted with T24 (anti–
Thy-1) ascites intraperitoneally. As TNFR2
 
2/2
 
 mice were gener-
ated in 129.SV-Ter (129) mice, RIP-mOVA.bm1 mice were re-
constituted with fetal liver cells from (B6 
 
3 
 
129)F1 embryos to
prevent rejection of adoptively transferred OT-I.TNFR2
 
2/2
 
 cells
carrying murine strain 129 minor histocompatibility determinants.
 
Results
 
Deletion of OT-I Cells Is Mediated by CD95 but Not
TNFR2.
 
We have previously shown that when OVA-
specific CD8
 
1
 
 T cells from the OT-I transgenic line (OT-I
cells) were adoptively transferred into RIP-mOVA mice,
which express OVA in the pancreatic islets and other tis-
sues, these cells were activated and proliferated in the
draining lymph nodes of OVA-expressing tissues (3), but
were deleted as a result of this process (4). The deletion of
CD8
 
1
 
 T cells induced by cross-presentation had originally
been demonstrated by following the fate of OT-I cells
adoptively transferred into B6
 
®
 
RIP-mOVA.bm1 bone
marrow chimeras (4). These chimeras expressed the MHC
class I molecule K
 
b
 
 on their bone marrow compartment,
and K
 
bm1
 
 on all other tissues. This provided the advantage
that only the bone marrow compartment could present
OVA to CD8
 
1
 
 T cells, allowing examination of the effect
of cross-presentation in the absence of direct presentation
by tissue cells expressing this antigen. Also, it allowed for
the transfer of large numbers of OT-I cells, which was nec-
essary for monitoring their survival by flow cytometry but
would otherwise have led to diabetes if islet 
 
b
 
 cells were
able to directly present OVA (4).
To explore the roles of CD95 and TNFR2 in the dele-
tion of CD8
 
1
 
 T cells, OT-I mice were crossed to either
CD95-deficient B6.
 
lpr
 
 mice, or to mice lacking TNFR2
(24). Survival of these cells was examined 6 wk after adop-
tive transfer into B6
 
®
 
RIP-mOVA.bm1 chimeras. For
OT-I.TNFR2
 
2/2
 
 cells, it was necessary to use (B6 
 
3
 
129)F1 bone marrow, since TNFR2-deficient mice con-
tained minor antigens of 129 origin that would otherwise
lead to rejection of OT-I.TNFR2
 
2/2
 
 cells. These experi-
ments revealed that deletion of OT-I cells did not require
TNFR2, since TNFR2-deficient OT-I cells, like wild-
type OT-I cells, were effectively deleted (Fig. 1). In con-
trast, CD95 signaling was necessary for the deletion pro-
cess, since OT-I.
 
lpr
 
 cells were not deleted but increased in
numbers relative to those transferred into nontransgenic lit-
termates (Fig. 2). These cells generated effective CTLs in
vitro in response to antigen, indicating that they were not
anergized in vivo (data not shown). These results led to the
conclusion that CD95 signaling was necessary for the dele-
tion of autoreactive CD8
 
1
 
 T cells.
 
The Initial Proliferation of OVA-specific CD8
 
1
 
 
 
T Cells (OT-I
Cells) Induced by Cross-presentation Is Not Affected by a Defi-
ciency in either CD95 or TNFR2.
 
There are two main pos-
sibilities to account for the lack of deletion of OT-I.
 
lpr
 
 cells
in RIP-mOVA mice: either CD95 was required directly
for the deletion signal, or else it participated in the initial
Figure 1. The deletion of
OT-I cells induced by cross-pre-
sentation is independent of
TNFR2. Fetal liver cells from
(B6 3 129)F1 embryos were
grafted into irradiated RIP-
mOVA.bm1 mice and nontrans-
genic littermates. 6 wk later, 6 3
106 OT-I cells or OT-I.
TNFR22/2 cells were adoptively
transferred, and after a further 6
wk the number of remaining
OT-I cells in the LNs and spleen was determined by flow cytometry.
These results are representative of two such experiments. 
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activation of OT-I cells preceding their deletion. To inves-
tigate whether CD95 or TNFR2 affected the proliferation
of OT-I cells induced by cross-presentation, CFSE-labeled
OT-I, OT-I.
 
lpr
 
, or OT-I.TNFR2
 
2/2
 
 cells were adoptively
transferred into RIP-mOVA mice. CFSE-labeling allows
visualization of cellular proliferation by detecting dilution
of the fluorescent dye by flow-cytometry, with each cell
cycle resulting in a halving of fluorescence intensity. This
technique has been used to compare the in vivo prolifera-
tive responses of T cells under different conditions (25).
The CFSE profiles of OT-I.
 
lpr
 
 and OT-I.TNFR2
 
2/2
 
 cells
in the renal LNs of RIP-mOVA mice were similar to those
of wild-type OT-I cells (Fig. 3), demonstrating an equiva-
lent proliferative response.
 
Upregulation of CD95 on OT-I Cells Activated by Cross-pre-
sentation.
 
These results suggested that the deletion of OT-I
cells induced by cross-presentation was mediated by CD95.
This molecule is constitutively expressed on CD8
 
1
 
 T cells
but is upregulated upon TCR-mediated activation in vitro
(8–12). To investigate whether CD95 is also upregulated
after activation by cross-presentation in vivo, the kinetics
of CD95-expression on OT-I cells was investigated on
OT-I cells proliferating in the renal LNs of RIP-mOVA
mice. This was achieved by comparing CD95 expression
on CFSE-labeled OT-I cells that had undergone 0–7 cell
cycles, separately. Indeed, CD95 expression increased with
the number of cell cycles completed (Fig. 4), suggesting
that one way cross-presentation renders CD8
 
1
 
 T cells sus-
ceptible to CD95-mediated signals is through upregulation
of this receptor. Such upregulation of CD95 was not seen
on OT-I.
 
lpr
 
 cells under the same conditions (data not
shown).
 
Discussion
 
The key role of CD95 in T cell tolerance became evi-
dent from the lymphoproliferative disease in 
 
lpr
 
 and 
 
gld
 
mice, which carry mutations of the CD95 and CD95L
Figure 2. The deletion of
OT-I cells induced by cross-pre-
sentation is mediated by CD95.
Bone marrow from B6 mice was
grafted into irradiated RIP-
mOVA.bm1 mice and non-
transgenic littermates. 22 wk
later, 5 3 106 OT-I cells or OT-
I.lpr cells were adoptively trans-
ferred, and after a further 6 wk
the number of remaining OT-I
cells in the LNs and spleen was
determined by flow cytometry.
These results are representative
of two such experiments.
Figure 3. Influence of CD95 and TNFR2 on the proliferation of OT-I
cells in vivo. 2 3 106 CFSE-labeled OT-I (top row), OT-I.lpr (center row),
and OT-I.TNFR22/2 (bottom row) cells were adoptively transferred into
RIP-mOVA mice. After 52 h, lymphocytes from the renal (left column),
pancreatic (center column), and nondraining inguinal LNs (right column)
were analyzed by flow cytometry. Profiles were gated on CFSE1
CD81PI2 cells. The numbers indicate the percentage of OT-I cells that
had proliferated in vivo. These results are representative of four such ex-
periments.
Figure 4. Upregulation of CD95 on OT-I cells activated by cross-pre-
sentation. 3 3 106 CFSE-labeled OT-I RAG2/2 cells were injected into
RIP-mOVA mice. After 3 d, the levels of CD95 expression on OT-I
cells that had undergone different numbers of cell cycles in the renal LN
was determined. These were identified in a FACSÒ dot-plot showing
CFSE versus CD8-PE fluorescence (A). The histograms show the expres-
sion of CD95 on the undivided cells (A0), cells that had divided once
(A1), cells that had undergone 2 divisions (A2), and so on up to seven di-
visions (A7). A marker was set arbitrarily to allow comparison of CD95
expression. The numbers indicate the percentage of OT-I cells that ex-
pressed a CD95 level higher than this marker. Dot-plot B shows undi-
vided OT-I cells from the inguinal LN of the same RIP-mOVA recipient
and histogram B0 shows their CD95 expression. Dot-plot C shows OT-I
cells in the renal LN of a nontransgenic recipient, and histogram C0
shows their CD95 expression. These results are representative of three
such experiments.418 Roles of CD95 and TNFR2 in the Peripheral Deletion of CD81 T Cells
genes, incapacitating these molecules (13, 14). In vitro
studies further demonstrated that CD95 can transduce a
death signal to activated T cells (26, 27). Activated CD41
T cells or T cell hybridomas were resistant to anti-CD3 or
superantigen-induced AICD when CD95 was blocked or
when T cells from lpr mice were used (8–12). These results
were verified in vivo by showing that superantigen-induced
T cell apoptosis was severely retarded in lpr mice (5, 28).
The crucial role of CD95 in controlling autoreactive
CD41 T cells was demonstrated in TCR transgenic mod-
els. In these studies, lack of CD95-function prevented
AICD of TCR transgenic CD41 T cells in the cytochrome
c model (6, 20) or when hen egg lysozyme was expressed as
a model autoantigen (21). However, in mice expressing a
hemagglutinin-specific TCR, blocking of TNF together
with CD95 prevented deletion induced by antigen injec-
tion more profoundly than did blocking of CD95 alone
(18). This suggested an additional role for TNF in mediat-
ing peripheral deletion of CD41 T cells. For CD81 T cells,
in vitro studies suggested that TNF, primarily via TNFR2,
played a more important role than CD95 for inducing
apoptosis (19, 29). Consistent with this idea, deletion in-
duced in vivo by viral infections was CD95 independent
(22, 23), and peptide-induced deletion of transgenic CD81
T cells was diminished in TNFR1 knockout mice (30).
A possible role for TNFR2 in the peripheral deletion of T
cells had originally been considered unlikely, since TNFR2
lacks the death-inducing domain present in TNFR1 and
CD95, and because TNFR2-knockout mice did not show
lymphoproliferative disease (24), which had been reported
to be MHC class I dependent (31). Furthermore, there was
in vitro evidence for a costimulatory role of TNFR2 sig-
naling in the activation of T cells (32, 33).
The roles of CD95 and TNFR2 in the peripheral dele-
tion of autoreactive CD81 T cells had not been extensively
investigated in vivo. We addressed this question using the
transgenic RIP-mOVA model in which cross-presentation
of a self-antigen induces deletion of autoreactive CD81 T
cells. Our results showed that this form of peripheral toler-
ance was mediated by CD95, and not by TNFR2. These
results demonstrate that CD95 can control autoreactive
CD81 T cells, unveiling a new role for CD95 in the main-
tenance of peripheral T cell tolerance. Furthermore, the
CD95 molecule itself was upregulated on the surface of
OT-I cells in vivo, suggesting that this may be linked to
rendering OT-I cells more receptive to CD95-induced
AICD. This in vivo upregulation of CD95 confirms previ-
ous in vitro studies demonstrating TCR-mediated induc-
tion of CD95-expression on the surface of CD41 T cell
hybridomas or lines (8–12).
CD95 has been shown to play a pivotal role in the dele-
tion of autoreactive B cells (34) and CD41 T cells (6, 18,
20, 21), and now we demonstrate a role for this molecule
in the control of autoreactive CD81 T cells. This contrasts
with the observation that deletion of CD81 T cells during
viral infection did not depend on CD95 (22, 23), suggest-
ing that a different homeostatic mechanism operates under
these conditions. Likewise, after challenge with a foreign
antigen, deletion of transgenic CD41 T cells was not de-
pendent on CD95 (21). This latter study concluded that in
contrast to the control of autoreactive T cells, the down-
regulation of T cells numbers at the end of a response to
foreign antigens is controlled by mechanisms other than
CD95, such as expression of genes of the bcl-2 family. Sur-
vival genes of this family are downregulated when activated
T cells cease to receive antigenic or costimulatory signals
(35, 36), resulting in death by neglect. This demarcation
between  bcl-2-mediated “passive” downregulation after
clearing foreign antigens and autoantigen-driven CD95-
mediated “active” control of autoreactive T cells is sup-
ported by studies showing that these two molecules are in-
volved in different intracellular apoptotic mechanisms (5).
At present, although foreign and self-antigens have been
suggested to induce sensitivity to different death pathways
(21), it is unclear what antigenic property is responsible for
this switch. Given that only a few antigens have been tested
thus far, it remains possible that the alternative outcomes
could simply be due to quantitative differences in antigen
dose or location (rather than to foreign versus self). How-
ever, the lack of CD95-sensitivity in response to ubiquitous
antigens derived from a viral pathogen (22, 23) versus the
sensitivity to this pathway when ubiquitous self-antigen is
available (21) (at least for CD41 T cells) suggests that quali-
tative differences may be important. One such difference
may be the availability of inflammatory signals associated
with infections, which may induce resistance to CD95-
mediated signaling (37).
In conclusion, we have demonstrated that CD95 plays
an important role in the deletion of autoreactive CD81 T
cells induced by cross-presentation of self-antigens, demon-
strating a further role for CD95 in the maintenance of self-
tolerance.
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